Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pragmatic randomized trial of fingolimod versus dimethyl fumarate in relapsing-remitting multiple sclerosis
2017-000559-26Phase 4Completed
- Sponsor
- Carlo Besta Neurological Institute
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in relapsing-remitting multiple sclerosis (RRMS) comparing Fingolimod with Dimethyl fumarate (2 arms). Primary endpoint: Time to loss of NEDA status. Started Sep 2021; status: completed.
02
Drugs
fingolimoddimethyl fumarate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2017-000559-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000559-26.